Literature DB >> 24250886

Pantothenate kinase 2 mutation with eye-of-the-tiger sign on magnetic resonance imaging in three siblings.

Mitra Ansari Dezfouli1, Elham Jaberi, Afagh Alavi, Mohammad Rezvani, Gholamali Shahidi, Elahe Elahi, Mohammad Rohani.   

Abstract

BACKGROUND: Pantothenate kinase associated neurodegeneration (PKAN) is the most prevalent type of neurodegeneration with brain iron accumulation (NBIA) disorders characterized by extrapyramidal signs, and 'eye-of-the-tiger' on T2 brain magnetic resonance imaging (MRI) characterized by hypointensity in globus pallidus and a hyperintensity in its core. All PKAN patients have homozygous or compound heterozygous mutation in PANK2 gene.
METHODS: Three sibling patients were diagnosed based on clinical presentations especially extrapyramidal signs and brain MRI. The exons and flanking intronic sequences of PANK2 were sequenced from DNA of leukocytes of the affected individuals.
RESULTS: All patients were homozygous for c.C1069T, p.R357W in PANK2 gene. This mutation is well conserved in the homologous protein of distally related spices.
CONCLUSION: In the current study we identified three siblings affected with PKAN, all of them have mutations in PANK2 gene. In MRI of all patients with PANK2 mutation eye-of-the-tiger sign was apparent.

Entities:  

Keywords:  Brain Iron Accumulation; Eye-of-the-Tiger sign; Neurodegeneration; PANK2 gene; Pantothenate Kinase Associated Neurodegeneration

Year:  2012        PMID: 24250886      PMCID: PMC3829266     

Source DB:  PubMed          Journal:  Iran J Neurol        ISSN: 2008-384X


Introduction

Neurodegeneration with brain iron accumulation (NBIA) encompasses a group of rare neurodegenerative diseases characterized by relentlessly progressive extrapyramidal signs and iron accumulation in the brain usually in the globus pallidus.[1, 2] The most prevalent form of NBIA is pantothenate kinase associated neurodegeneration (PKAN) also known as NBIA-1 which accounts for approximately half of the cases of NBIA.[3] This syndrome first described by Julius Hallervorden and Hugo Spatz in 1922;[4] however, their involvement with Nazi extermination politics lead to discredit them.[5] PKAN syndrome is characterized by autosomal recessive inheritance and the ‘eye of the tiger’ pattern of iron accumulation in the pallidum on T2 weighted magnetic resonance imaging (MRI) which is caused by iron deposition in the periphery (hypointensity) and necrosis on its core (hyperintensity).[6, 7] Clinical presentations include dystonia, dysarthria, and dysphasia. Dementia, severe mental retardation and severe movement disability may develop at later stages.[8] Rare clinical features include rigidity, parkinsonism, choreoathetosis, seizures, optic atrophy, and pigmentary retinopathy. Based on age at onset and rate of progression, PKAN can be classified in two major forms. In the classic form of PKAN, onset is usually in the first decade of life. Visual impairment caused by optic atrophy or retinal degeneration have been described in some classical cases. Atypical PKAN is presented in the second decade of life with slow progression. Neurobehavioral disorders and seizure are common in atypical form.[3] All PKAN cases have mutation in PANK2 gene located on 20p13.[9] PANK2 encodes a mitochondrial pantothenate kinase which is the key regulatory enzyme in coenzyme A biosynthesis.[10] In the current study, we report clinical and genetic findings of three PKAN patients from an Iranian family.

Materials and Methods

Three sibling patients were diagnosed based on clinical presentations especially extrapyramidal signs and brain MRI findings of iron deposition in the globus pallidus. Details of clinical information and familial reputation (hisotor and information) were obtained and blood samples were collected from all patients after they had given informed consent. This research was performed in accordance with the Declaration of Helsinki and with approval of the ethics board of the University of Tehran. Participants or their guardians consented to participate after being informed of the nature of the research. Primers were designed to amplify all eight exons. The exons and flanking intronic sequences of PANK2 were amplified from DNA of leukocytes of the affected individuals. Amplicons were sequenced using the ABI Big Dye terminator chemistry and an ABI Prism 3700 instrument (Applied Biosystems, Foster City, CA). Sequences were analyzed with the Sequencher software (Gene Codes Corporation, Ann Arbor, MI). Obtained DNA sequences were compared to NG_008131.1, NM_024960.4, and NP_705902.2. To determin the extent of amino acids conservation and the effect of DNA variations, we attained homologous proteins amino acid sequences of other species from ENSEMBL (http://www.ensembl.org/index.html) and aligned using the ClustalW2.0 software (http://www.ebi.ac.uk/Tools/msa/clustalw2/).

Results

PANK2 mutation was found in all three patients. Patients born to consanguineous family with no familial history of neurological disease and had homozygous mutations in PANK2 gene. All these three patients had eye-of-the-tiger signs in T2 weighed brain MRI (Fig. 1).
Figure 1

T2 weighted Brain magnetic resonance imaging of the patient I which shows a central hyperintensity within a surrounding area of hypointensity in globus pallidus (eye-of-the-tiger)

T2 weighted Brain magnetic resonance imaging of the patient I which shows a central hyperintensity within a surrounding area of hypointensity in globus pallidus (eye-of-the-tiger) Case I was 24 years old and suffered from progressive dystonia. He was normal at birth and during early developmental periods. At the age 10, he complained from stiffness in his hands and 2 years later dystonia appeared in his upper limbs. Oromandibular dystonia caused problems in feeding. On exam he had severe dysarthria, dystonia (more prominent in hands and oromandibular region), Babinski sign and tremor in hands. Case II was 18 years old girl and at the age of 10 her parents noticed stiffness and resting tremor in his upper and later in lower limbs and poor balance in usual movements and progressive difficulty in walking. She had severe hand dystonia and orolingual dystonia with recurrent lips and tongue biting. She could not walk without aid and was dependent for all daily living activities. Case III was a 17 years old boy with normal early development. At the age 9, dystonia appeared in upper limbs. One year later, dysarthria, dysphasia and gait disturbance were added to the symptoms. Pursuit eye movements were fragmented and the saccades were slow. All three patients were found to be homozygous for a mutation in exon 3 of the gene which resulted in a change of arginine to tryptophan at amino acid position 357 in pantothenate kinase2 enzyme (Fig. 2). This mutation have been previously reported by Zhou et al.[9] Importantly, this amino acid position is completely conserved in homologous proteins (Table 1).
Figure 2

Chromatograms include mutations in each patient, the last one shows normal sequence

Table 1

Evolutionary conservation of amino acids affected by PANK2 Mutation in homologous proteins

OrganismsTranscript IDp.R357W
homo sapiens (hPANK2)ENST00000316562SVGFNGRSQCYY
Pan troglodytesENSPTRT00000047902SVGFNGRSQCYY
Nomascus leucogenysENSNLET00000009772SVGFNGRSQCYY
Macaca mulattaENSMMUT00000028051SVGFNGRSQCYY
Loxodonta africanaENSLAFT00000003123SVGFNGRSQCYY
Pongo abeliiENSPPYT00000012548SVGFNGRSQCYY
Bos taurusENSBTAT00000045589SVGFNGRSECYY
Chromatograms include mutations in each patient, the last one shows normal sequence Evolutionary conservation of amino acids affected by PANK2 Mutation in homologous proteins

Discussion

There are evidences for the existence of an isoform of PANK2 in mitochondrial in which the disease is caused by loss of function of this isoform.[10, 11] The PANK2 gene expresses abundantly in the brain.[9] It is predicted that the preprotein has 29 amino acid mitochondrial target sequence at the amino terminus.[11] Pantothenate kinase enzyme catalyzes the first and the most important rate controlling step of coenzyme A biosynthesis by phosphorylation of pantothenate (vitamin B5) to phosphopantothenate which is rapidly enter in the coenzyme A biosynthesis.[12] In its acetyl form, coenzyme A contributes in tricarboxylic acid cycle and fatty acids beta oxidation as an acyl carrier. In the backward feedback coenzyme A and its thioester form can inhibit pantothenate kinase by binding to ATP binding site of the enzyme.[13] The exact pathogenic mechanisms of the disease are unknown, but it has been suggested that stop production of phosphopantothenate causes accumulation of cysteine at the later stage of coenzyme A production and this surplus mass of cysteine can cause accumulation of excess iron in the brain and tissue damage by promoting oxidative stress.[9, 14] In this study, we identified three siblings affected with PKAN; all of them had mutations in PANK2 gene. On brain MR imaging of all patients with PANK2 mutation “eye of the tiger” sign was apparent. However, it should be considered that other rare diseases like Karak syndrome and some cases with CO poisoning can show eye of the tiger sign.[7, 15] On the other hand, there are a few cases with mutation in PANK2 and iron deposition in the globus pallidus without eye-of-the-tiger sign.[16, 17] It has been suggested that sometimes with the disease progression and iron deposition in the globus pallidus the central hyperintense signal and eye-of-the-tiger disappears.[16]
  15 in total

1.  Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum.

Authors:  A Mubaidin; E Roberts; D Hampshire; M Dehyyat; A Shurbaji; M Mubaidien; A Jamil; A Al-Din; A Kurdi; C G Woods
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

2.  Pantothenate kinase 2 mutation with classic pantothenate-kinase-associated neurodegeneration without 'eye-of-the-tiger' sign on MRI in a pair of siblings.

Authors:  Zarazuela Zolkipli; Hisham Dahmoush; Dawn E Saunders; W K Kling Chong; Robert Surtees
Journal:  Pediatr Radiol       Date:  2006-06-07

Review 3.  Coenzyme A: back in action.

Authors:  Roberta Leonardi; Yong-Mei Zhang; Charles O Rock; Suzanne Jackowski
Journal:  Prog Lipid Res       Date:  2005-04-20       Impact factor: 16.195

4.  Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation.

Authors:  Monika B Hartig; Konstanze Hörtnagel; Barbara Garavaglia; Giovanna Zorzi; Tomasz Kmiec; Thomas Klopstock; Kevin Rostasy; Marina Svetel; Vladimir S Kostic; Markus Schuelke; Evelyn Botz; Adolf Weindl; Ivana Novakovic; Nardo Nardocci; Holger Prokisch; Thomas Meitinger
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

5.  Pantothenate kinase regulation of the intracellular concentration of coenzyme A.

Authors:  C O Rock; R B Calder; M A Karim; S Jackowski
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

6.  Iron on the brain.

Authors:  T A Rouault
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

7.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome.

Authors:  B Zhou; S K Westaway; B Levinson; M A Johnson; J Gitschier; S J Hayflick
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

Review 8.  Clinical and genetic delineation of neurodegeneration with brain iron accumulation.

Authors:  A Gregory; B J Polster; S J Hayflick
Journal:  J Med Genet       Date:  2008-11-03       Impact factor: 6.318

9.  An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria.

Authors:  Konstanze Hörtnagel; Holger Prokisch; Thomas Meitinger
Journal:  Hum Mol Genet       Date:  2003-02-01       Impact factor: 6.150

Review 10.  Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations.

Authors:  Susanne A Schneider; John Hardy; Kailash P Bhatia
Journal:  Mov Disord       Date:  2011-10-26       Impact factor: 10.338

View more
  1 in total

1.  A Novel Nonsense Mutation in PANK2 Gene in Two Patients with Pantothenate Kinase-Associated Neurodegeneration.

Authors:  Soudeh Ghafouri-Fard; Vahid Reza Yassaee; Alireza Rezayi; Feyzollah Hashemi-Gorji; Nasrin Alipour; Mohammad Miryounesi
Journal:  Int J Mol Cell Med       Date:  2016-10-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.